These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 9718357)
21. Alkaptonuria - Many questions answered, further challenges beckon. Davison AS; Hughes AT; Milan AM; Sireau N; Gallagher JA; Ranganath LR Ann Clin Biochem; 2020 Mar; 57(2):106-120. PubMed ID: 31529982 [No Abstract] [Full Text] [Related]
22. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lindstedt S; Holme E; Lock EA; Hjalmarson O; Strandvik B Lancet; 1992 Oct; 340(8823):813-7. PubMed ID: 1383656 [TBL] [Abstract][Full Text] [Related]
23. Use of nitisinone in patients with alkaptonuria. Suwannarat P; O'Brien K; Perry MB; Sebring N; Bernardini I; Kaiser-Kupfer MI; Rubin BI; Tsilou E; Gerber LH; Gahl WA Metabolism; 2005 Jun; 54(6):719-28. PubMed ID: 15931605 [TBL] [Abstract][Full Text] [Related]
24. Interference of hydroxyphenylpyruvic acid, hydroxyphenyllactic acid and tyrosine on routine serum and urine clinical chemistry assays; implications for biochemical monitoring of patients with alkaptonuria treated with nitisinone. Curtis SL; Norman BP; Milan AM; Gallagher JA; Olsson B; Ranganath LR; Roberts NB Clin Biochem; 2019 Sep; 71():24-30. PubMed ID: 31228435 [TBL] [Abstract][Full Text] [Related]
25. Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1. Santra S; Baumann U Expert Opin Pharmacother; 2008 May; 9(7):1229-36. PubMed ID: 18422479 [TBL] [Abstract][Full Text] [Related]
26. Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report. Grompe M; Overturf K; al-Dhalimy M; Finegold M J Inherit Metab Dis; 1998 Aug; 21(5):518-31. PubMed ID: 9728332 [TBL] [Abstract][Full Text] [Related]
27. Corneal opacities associated with NTBC treatment. Ahmad S; Teckman JH; Lueder GT Am J Ophthalmol; 2002 Aug; 134(2):266-8. PubMed ID: 12140036 [TBL] [Abstract][Full Text] [Related]
28. The fate of tyrosinaemic Hungarian patients before the NTBC aera. László A; Rózsa M; Sallay E; Tiszlavicz L; Janovszky A; Várkonyi A; Karg E; Wittmann G; Túri S; Ugarte M Ideggyogy Sz; 2013 Nov; 66(11-12):415-9. PubMed ID: 24555242 [TBL] [Abstract][Full Text] [Related]
29. A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. Introne WJ; Perry MB; Troendle J; Tsilou E; Kayser MA; Suwannarat P; O'Brien KE; Bryant J; Sachdev V; Reynolds JC; Moylan E; Bernardini I; Gahl WA Mol Genet Metab; 2011 Aug; 103(4):307-14. PubMed ID: 21620748 [TBL] [Abstract][Full Text] [Related]
30. [Evolution of a case of tyrosinemia type I treated with NTBC]. Ros Viladoms J; Vilaseca Buscà MA; Lambruschini Ferri N; Mas Comas A; González Pascual E; Holme E An Esp Pediatr; 2001 Mar; 54(3):305-9. PubMed ID: 11262262 [TBL] [Abstract][Full Text] [Related]
31. [Late onset type I tyrosinemia]. Klujber V; Sallai A; Kálmánchey R; Szönyi L; Hosszú E Orv Hetil; 1997 Jul; 138(28):1805-8. PubMed ID: 9280876 [TBL] [Abstract][Full Text] [Related]
32. Peripheral neuropathy as the presenting feature of tyrosinaemia type I and effectively treated with an inhibitor of 4-hydroxyphenylpyruvate dioxygenase. Gibbs TC; Payan J; Brett EM; Lindstedt S; Holme E; Clayton PT J Neurol Neurosurg Psychiatry; 1993 Oct; 56(10):1129-32. PubMed ID: 8410015 [TBL] [Abstract][Full Text] [Related]
34. Osteoarticular cells tolerate short-term exposure to nitisinone-implications in alkaptonuria. Mistry JB; Jackson DJ; Bukhari M; Taylor AM Clin Rheumatol; 2016 Feb; 35(2):513-6. PubMed ID: 26024586 [TBL] [Abstract][Full Text] [Related]
35. Neurocognitive outcome in patients with hypertyrosinemia type I after long-term treatment with NTBC. Thimm E; Richter-Werkle R; Kamp G; Molke B; Herebian D; Klee D; Mayatepek E; Spiekerkoetter U J Inherit Metab Dis; 2012 Mar; 35(2):263-8. PubMed ID: 22069142 [TBL] [Abstract][Full Text] [Related]
36. Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice. Mayorandan S; Meyer U; Gokcay G; Segarra NG; de Baulny HO; van Spronsen F; Zeman J; de Laet C; Spiekerkoetter U; Thimm E; Maiorana A; Dionisi-Vici C; Moeslinger D; Brunner-Krainz M; Lotz-Havla AS; Cocho de Juan JA; Couce Pico ML; Santer R; Scholl-Bürgi S; Mandel H; Bliksrud YT; Freisinger P; Aldamiz-Echevarria LJ; Hochuli M; Gautschi M; Endig J; Jordan J; McKiernan P; Ernst S; Morlot S; Vogel A; Sander J; Das AM Orphanet J Rare Dis; 2014 Aug; 9():107. PubMed ID: 25081276 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of para-Hydroxyphenylpyruvate Dioxygenase by Analogues of the Herbicide Nitisinone As a Strategy to Decrease Homogentisic Acid Levels, the Causative Agent of Alkaptonuria. Laschi M; Bernardini G; Dreassi E; Millucci L; Geminiani M; Braconi D; Marzocchi B; Botta M; Manetti F; Santucci A ChemMedChem; 2016 Apr; 11(7):674-8. PubMed ID: 26947423 [TBL] [Abstract][Full Text] [Related]
38. From Weed Killer to Wonder Drug. Lock EA Adv Exp Med Biol; 2017; 959():175-185. PubMed ID: 28755195 [TBL] [Abstract][Full Text] [Related]
39. Perturbations of tyrosine metabolism promote the indolepyruvate pathway via tryptophan in host and microbiome. Gertsman I; Gangoiti JA; Nyhan WL; Barshop BA Mol Genet Metab; 2015 Mar; 114(3):431-7. PubMed ID: 25680927 [TBL] [Abstract][Full Text] [Related]
40. Diagnosis and management of tyrosinemia type I. Holme E; Lindstedt S Curr Opin Pediatr; 1995 Dec; 7(6):726-32. PubMed ID: 8776026 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]